Stroke thrombolysis in the elderly: risk or benefit?
Hemphill
J Claude
JC
Lyden
Patrick
P
D000367:Age Factors; D000368:Aged; D000375:Aging / Q000502:physiology*; D002545:Brain Ischemia / Q000503:physiopathology / Q000628:therapy*; D002543:Cerebral Hemorrhage / Q000139:chemically induced* / Q000401:mortality; D015331:Cohort Studies; D000075202:Contraindications; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects*; D006801:Humans; D008297:Male; D018579:Patient Selection / Q000941:ethics; D012189:Retrospective Studies; D018570:Risk Assessment; D020521:Stroke / Q000503:physiopathology / Q000628:therapy*; D015996:Survival Rate / Q000639:trends; D015912:Thrombolytic Therapy / Q000009:adverse effects*; D010959:Tissue Plasminogen Activator / Q000009:adverse effects; D016896:Treatment Outcome; D028761:Withholding Treatment / Q000941:ethics
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator